文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

重症流感与COVID-19:一项全国性病例对照比较研究

Critical Influenza and COVID-19-A Comparative Nationwide Case-Control Study.
PubMed 文献 · Crit Care Explor · 2022-05-16
一句话结论全国性匹配病例对照研究显示,重症流感与COVID-19的危险因素谱总体相似,但高血压对重症COVID-19风险更强,β受体阻滞剂、口服抗凝药和血小板抑制剂降低COVID-19 ICU入住风险而非流感。

该研究为瑞典全国性回顾性匹配病例对照研究(患者:对照=1:5),纳入2014年至2020年9月所有入住ICU的成人流感(1873例,对照9365例)和COVID-19(2567例,对照12835例)患者,按性别、年龄和地理区域匹配。流感ICU患者年龄更大、男性比例更低、合并症负担更重、简化急性生理学评分III更高,但短期死亡率与COVID-19患者相似。两者入住ICU时的危险因素谱(社会经济、精神及多种躯体变量)基本相当;高血压对重症COVID-19是更强的危险因素,非糖皮质激素免疫抑制治疗与重症流感相关而与COVID-19无关。病前使用他汀类和肾素-血管紧张素-醛固酮系统抑制剂降低两种疾病风险,糖皮质激素药物则相反;β受体阻滞剂、口服抗凝药和血小板抑制剂降低重症COVID-19风险但不降低流感风险。

要点

  • 高血压是重症COVID-19更强的危险因素(与流感相比),而非糖皮质激素免疫抑制治疗与重症流感相关但与COVID-19无关。
  • 病前使用他汀类和肾素-血管紧张素-醛固酮系统抑制剂降低重症流感和COVID-19两种疾病风险,糖皮质激素药物则增加风险。
  • β受体阻滞剂、口服抗凝药和血小板抑制剂降低重症COVID-19的ICU入住风险,但不降低重症流感风险。
  • 流感ICU患者年龄更大、男性比例更低、合并症负担更重、简化急性生理学评分III更高,但短期死亡率与COVID-19患者相似。
  • 两者入住ICU时社会经济、精神及多种躯体危险因素谱基本相当。

适用人群与场景

  • 2014年至2020年9月期间入住瑞典ICU的所有成人流感或COVID-19患者,以及按性别、年龄和地理区域1:5匹配的对照人群。

诊断标准与关键阈值

  • 研究终点为入住ICU。

研究设计与关键结果

  • 全国性回顾性匹配病例对照研究,纳入1873例流感ICU患者和9365例对照,2567例COVID-19 ICU患者和12835例对照,按性别、年龄和地理区域1:5匹配。
  • 流感ICU患者年龄更大、男性比例更低、合并症负担更重、简化急性生理学评分III更高,但短期死亡率与COVID-19患者相似。
  • 入住ICU时危险因素谱(社会经济、精神及多种躯体变量)在重症流感和COVID-19之间基本相当。
  • 高血压是重症COVID-19更强的危险因素(与流感相比);非糖皮质激素免疫抑制治疗与重症流感相关但与COVID-19无关。
  • 病前使用他汀类和肾素-血管紧张素-醛固酮系统抑制剂降低重症流感和COVID-19两种疾病风险,糖皮质激素药物则相反。
  • β受体阻滞剂、口服抗凝药和血小板抑制剂降低重症COVID-19的ICU入住风险,但不降低重症流感风险。

证据类型、等级与局限

  • 研究类型:全国性回顾性匹配病例对照研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,重症流感和COVID-19的危险因素谱总体相似,但存在重要差异:高血压对重症COVID-19风险更强,β受体阻滞剂、口服抗凝药和血小板抑制剂降低COVID-19 ICU入住风险但不降低流感风险;这些发现可能反映两种疾病病理生理机制的差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: Refined knowledge of risk factors for critical influenza and COVID-19 may lead to improved understanding of pathophysiology and better pandemic preparedness.

OBJECTIVES: To compare risk-factor profiles of patients admitted to intensive care with critical influenza and COVID-19.

DESIGN SETTING AND PATIENTS: A nationwide retrospective matched case-control study, including all adults admitted to an ICU in Sweden with influenza or COVID-19 between 2014 and September 2020 and a matched control population (ratio 1:5, patients:controls).

MEASUREMENTS AND MAIN RESULTS: Admission to an ICU. The study included 1,873 influenza and 2,567 COVID-19 ICU patients, and 9,365 and 12,835 controls, respectively, matched on sex, age, and geographical region. Influenza patients were older and less likely male, and carried a larger burden of comorbidity and a higher Simplified Acute Physiology Score III score, whereas short-term mortalities were similar when compared to COVID-19 patients. The risk-factor profiles at ICU admission were largely comparable including socioeconomic, psychiatric, and several somatic variables. Hypertension was a strong risk factor in critical COVID-19 patients compared with influenza. Nonglucocorticoid immunosuppressive therapy was associated with critical influenza but not COVID-19. Premorbid medication with statins and renin-angiotensin-aldosterone system inhibitors reduced the risk for both conditions, the opposite was a seen for glucocorticoid medication. Notably, medication with betablockers, oral anticoagulation, and platelet inhibitors reduced the risk of critical COVID-19 but not influenza.

CONCLUSIONS: The risk-factor profiles for critical influenza and COVID-19 were largely comparable; however, some important differences were noted. Hypertension was a stronger risk factor for developing critical COVID-19, whereas the use of betablockers, oral anticoagulants, and platelet inhibitors all reduced the risk of ICU admission for COVID-19 but not influenza. Findings possibly reflected differences in pathophysiological mechanisms between these conditions.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Larsson E, Eriksson J, Eriksson M, et al. Critical Influenza and COVID-19-A Comparative Nationwide Case-Control Study. Crit Care Explor. 2022. PMID: 35620773. doi:10.1097/CCE.0000000000000705

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。